Pfizer teams with SpringWorks to evaluate PF‐06863135 + nirogacestat in multiple myeloma

• Pfizer (NYSE:PFE) has entered into a clinical trial collaboration agreement with SpringWorks Therapeutics (NASDAQ:SWTX) to evaluate the latter's investigational gamma secretase inhibitor (GSI), nirogacestat, in combination with Pfizer’s anti-B-cell maturation antigen (BCMA) CD3 bispecific antibody, PF‐06863135, in patients with relapsed or refractory multiple myeloma.
• Under the terms of the agreement, Pfizer will sponsor and conduct the Phase 1b/2 study to evaluate the safety, tolerability and preliminary efficacy of the combination, and will assume all costs associated with the study, other than expenses related to the manufacturing of nirogacestat and expenses related to intellectual property rights.
• Both the companies will also form a joint development committee to manage the clinical study, which is expected to commence in H1 2021.
• In addition, SpringWorks is also currently conducting a global Phase 3, double-blind, placebo-controlled clinical trial (the DeFi Trial) to evaluate nirogacestat in adults with progressing desmoid tumors.
• https://seekingalpha.com/news/3619700-pfizer-teams-up-springworks-to-evaluate-pf-06863135-nirogacestat-in-multiple-myeloma